Your position:Home >> Pro. Lib >> Biomedicine  Biomedicine
"Innovative new anti ulcer drugs"
come from:jinhui | time:2014-2-24 | views:

  Anti ulcer drugs to achieve innovative high acid suppressive activity and reduce side effects, can replace the use of proton pump inhibitors.

Business opportunity
  Peptic ulcer is one of the most common diseases of internal organs, adults up to 5-10% of 2-3% adults in developed countries and the brics. More than 20% of adults will -- gastroesophageal reflux disease with common complications. This acid related disease accounts for third share of the global pharmaceutical market, turnover of more than $30000000000. Proton pump inhibitor (PPIs) is the current standard of care and the most potent inhibitor of gastric acid secretion, however, proton pump inhibitors also failed to meet specific needs, based on additional physiological indicators and treatment is available on a new drug to improve treatment times.

The unmet need
  In a drug candidates have been identified in Russia's Tomsk region innovation pharmacological research company, pre clinical studies in the recent, can solve the traditional proton pump inhibitors and other clinical gap generated from the current standard of care.
Clinical gap including:
  1, stable inhibition of gastric acid secretion and secretory cell atrophy
  2, serious complications, such as digestive disorders, tumor development, transmission of Helicobacter pylori infection
  3, headache, diarrhea, allergic reactions and male breast dysplasia syndrome etc.
  These side effects have caused the global top scientists and large pharmaceutical enterprises concern, however, in the work of clinical trials and drug development of innovation and discovery the therapeutic areas is still very lack.

  Pharmacological research and innovation innovation company puts forward the comprehensive development of the anti ulcer medicine is an effective H+, K+-ATPhase reversible inhibitor, inhibition constant I50 = 10-6 M.
  This invention has many advantages:
  1, new molecules with proton pump mechanism, patented. Compared with the known compounds, the new drug is a reversible inhibitor, which is an important competitive advantage it;
  2, do not inhibit the basic (normal) level of gastric secretion, inhibit excessive secretion of hydrochloric acid, only;
  3, reversible proton pump inhibitors and potassium is not competitive; potassium ion can enhance the inhibitory effect of drugs;
  4, the anti ulcer activity comparable to the current market is mainly the same kind of drugs, and has higher security;
  In short, this drug is more effective method for the treatment of drug developers provide attractive investment opportunities are looking for in the treatment field.
  Jin Hui International is willing to communicate with the development of the new drug interested companies and investors.